Cytori Therapeutics
Die Nachricht ist vom 15.10.
Cytori Secures $15 Million Loan Facility Led by GE Healthcare Financial Services
Cytori Therapeutics (News) (NASDAQ: CYTX) has entered into a $15 million loan facility with GE (News/Aktienkurs) Healthcare Financial Services and Silicon Valley Bank. An initial term loan of $7.5 million, minus fees and expenses, funded October 14, 2008. Cytori will be able to exercise the additional $7.5 million term loan on or before December 12, 2008, provided the Company meets certain financial prerequisites established by the lenders.
GE Healthcare Financial Services' financing solution will be used to support the commercialization of Cytori's recently launched Celution® System and StemSource® Cell Bank in Europe and Asia. In addition, the funds will support product pipeline development and general corporate activities. Securing this loan facility further demonstrates Cytori's ability to attract funding from well regarded sources.
”GE is very pleased to provide capital in support of Cytori's growth initiatives,“said Anthony Storino, senior managing director, GE Healthcare Financial Services' life science finance group. ”Their innovative technologies are shaping the future of the reconstructive surgery markets.“
For almost two decades, the life science finance team of GE Healthcare Financial Services has worked with more than 500 companies throughout the United States, Canada and Europe. With a dedicated focus on assisting life science companies large and small, from the first venture round to post-IPO, the team has provided over $2.5 billion in financing to the market.
About Cytori
Cytori's (NASDAQ: CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution® 800 System is being introduced in Europe into the reconstructive surgery market while the Celution® 900 System is being commercialized globally for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs.
link:http://www.finanznachrichten.de/...chten-2008-10/artikel-12033791.asp
Äusserst ungewöhnlich, noch dazu in der aktuellen Zeit Kredit zu bekommen. Normalerweise gibts nur venture capital und KEs.
Hier wird aber die Finanzierung einer Produktionslinie für Vertriebsbeginn im Laufe 2009 sichergestellt. Naja, der Markt will Gewinne sehen. Die gibts 2008 noch nicht, aber offensichtlich glauben Kreditgeber jetzt schon dran....
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
Madonnas neues Gesicht: Mit 50 aussehen wie 35 dank Neuer Kosmetischer Chirurgie
Wien (pts/04.11.2008/09:35) - Plastik-Chirurgie, Facelifts und Lidkorrekturen, bis dato unverzichtbares Vademecum alternder Hollywooddiven, kommen zunehmend aus der Mode. War zwischenzeitlich das "New Face" in Hollywood bei Angelina Jolie und Demi Moore angesagt, verwenden nun Hollywooddiven wie Madonna vermehrt die Methoden der Neuen Kosmetischen Chirurgie, um ihre Gesichtszüge und Körperformen zu verjüngen.
In der Neuen Kosmetischen Chirurgie werden altersbedingte Veränderungen des Gesichtes und des Körpers anstatt mit Liftings und Silikon sorgsam mittels körpereigenem, Stammzell-angereichertem Fett ausgeglichen.
"Madonna ist ein gutes Beispiel für perfekte Verjüngung des Gesichtes mittels Eigenfett", sagt DDr. Heinrich, Experte für Kosmetische Chirurgie und Anti-Aging-Medizin in Wien. Die modernste Methode der Eigenfett-Anwendung, derentwegen Patientinnen aus der ganzen Welt, sogar aus Beverly Hills, zu DDr. Heinrich nach Wien kommen, ist die Verwendung von mit körpereigenen Stammzellen angereichertem Eigenfett. Dies erspart Frauen bei Brustvergrößerung und Gesichtsverjüngung Skalpell, Plastik und Silikon und bedeutet eine wesentliche Verbesserung von Gesundheit und Lebensqualität: "Eigenfett ist das optimale, natürliche Füllmaterial und hat außerdem einen lokal verjüngenden Effekt, wenn man es mit körpereigenen Stammzellen anreichert", sagt DDr. Karl-Georg Heinrich, der diese Methoden als erster Mediziner Europas anbietet.
Bei diesem Verfahren wird zunächst Körperfett schonend mit speziellen Mikrokanülen abgesaugt. Nach Anreicherung mit körpereigenen Stammzellen wird das Fett mit ästhetischem Feingefühl in das Gesicht bzw. in die Brust injiziert, ohne daß dabei sichtbare Narben entstehen. Dies erfolgt wahlweise unter örtlicher Betäubung oder Dämmerschlaf ohne Vollnarkose. Der Nachsorgeaufwand ist gering, die Patientin wird nach dem Eingriff nach Hause entlassen und ist voll mobil.
Die Haltbarkeit und Unbedenklichkeit von Stammzell-angereichertem Eigenfett zur Brustrekonstruktion, z.B. nach Krebsoperationen, zur kosmetischen Brustvergrößerung und auch zur ästhetischen Gesichtsverjüngung wurde mittlerweile in klinischen Studien aus Japan und den USA erwiesen.
Weitere Informationen unter http://www.neuekosmetischechirurgie.com
Dr. Heinrich in Wien arbeitet mit dem Cellution System von Cytori....
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
cytx.png (verkleinert auf 79%)
könnte es sein,dass cytori pleite ist,bevor es richtig losgeht ? Sind knapp bei Kasse,was ?!
Ansonsten find ich den wert echt klasse und würde gerne einsteigen ....
MFG
Chali
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Cytori Therapeutics |
MFG
Chali
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Cytori Therapeutics |
Ob Cytori Pleitegeht? Eher nicht. Sie haben ja jetzt sogar Fremdkapital bekommen. Ausserdem haben sie auch Großaktionäre an Board. ABer "nicht pleite" und "Erfolg für Altaktionäre" sind bekanntlich 2 paar Stiefel. Es wird Zeit für einen echten Vertriebserfolg, einen Deal mit upfront.
Ansonsten kommen die Geräteumsätze ja wirklich in Schwung, so dass 2009 möglicherweise der Cashflow ausreichen wird, je nachdem, wie viele Studien man noch finanziert.
Bei diesen lächerlichen Kursen kann man eigentlich nur guiter Dinge sein....
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
cytx.png (verkleinert auf 79%)
Trotzdem natürlich insgesamt ein trauriges Niveau.....
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
cytx.png (verkleinert auf 79%)
Adipose Stem & Regenerative Cell Clinical Study Underwayfor Treatment of Chronic Radiation Injury
NAGASAKI, Japan, Dec 18, 2008 (BUSINESS WIRE) --
Cytori (NASDAQ: CYTX) announced that the first patient was enrolled in an investigator-initiated study using adipose-derived stem and regenerative cells to treat the chronic effects of radiation-induced local tissue injury. The 30-patient study is being conducted independently by Nagasaki University Hospital in Japan. Cytori's Celution(R) 800 System is being used to process and extract patients' own adipose tissue-derived stem and regenerative cells.
Radiation-related tissue injury, poor wound healing, and deep skin ulcers are among the serious effects of cancer therapy and may also occur from exposure to nuclear materials. "Currently, few treatment options exist for these patients," said Dr. Sadinori Akita, assistant professor of surgery at Nagasaki University and principal investigator of the study. "Based on the early result of the first case and the more than 300 various clinical cases performed to date using the Celution 800 System output, we believe Cytori's regenerative medicine technology has the potential to become a standard of care for a very large group of patients with injuries resulting from radiation exposure."
The study is being funded from a portion of a five year, $15 million grant awarded to Nagasaki University by the Ministry of Education, Sports, and Culture of Japan. The University is also home to the Global Strategic Center for Radiation Health Risk Control, an international consortium on radiation and atomic bomb injury research and medicine (www-sdc.med.nagasaki-u.ac.jp/gcoe/index.html). The Center emerged in the recovery from the historical atomic disaster suffered by Nagasaki, and is aligned with the World Health Organization (WHO), the International Atomic Energy Commission (IAEC) and the International Agency for Research on Cancer (IARC).
Nagasaki University is sponsoring one of several independent, investigator-initiated clinical studies, which are expected to begin around the world in 2008 and 2009 using Cytori's Celution(R) 800 System. "This study is important to Cytori," said Marc H. Hedrick, M.D., president of Cytori. "Our Celution(R) System will be used by a worldwide leader in radiation damage research and creating potential opportunities for Cytori to work more closely with the WHO and IARC. Ultimately these relationships in combination with a successful study could result in the Celution(R) System becoming a standard therapy for radiation-related disease."
About Cytori
Cytori's (NASDAQ: CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution(R) 800 System is being introduced in Europe into the reconstructive surgery market while the Celution(R) 900 System is being commercialized globally for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
SOURCE: Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.
Tom Baker, 858.875.5258
tbaker@cytoritx.com
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
Cytori Forms Commercialization Partnership with GE Healthcare
Monday January 12, 7:00 am ET
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ: CYTX - News) today announced the formation of a partnership with GE Healthcare to commercialize Cytori’s Celution® System in select European countries. The Celution System is a European-approved, state-of-the-art cell processing device, which extracts and makes a dose of a patient’s own adipose tissue-derived adult stem and regenerative cells available at the point-of-care. As part of the new relationship, GE Healthcare will commercialize the Celution System in the areas of cosmetic and reconstructive surgery, translational medicine, and stem cell banking in combination with Cytori’s StemSource® Cell Bank product.
“The addition of Cytori’s Celution System to GE Healthcare’s Cell Technologies portfolio demonstrates our commitment to the field,” says Sarah Bork, Director for GE Healthcare’s Cell Technologies Program. “Adipose tissue is emerging as one of the leading sources for adult stem and regenerative cells, and Cytori’s Celution System can provide patients’ own cells at the bedside. Its quality and ease-of-use, coupled with the demand from hospitals and surgeons for cells, underscore the growth potential of this system in regenerative medicine.”
“GE Healthcare will immediately broaden our access to customers in Europe and should greatly expand our Celution System installed base,” said Christopher J. Calhoun, chief executive officer for Cytori. “We will benefit from their existing hospital relationships and their established regenerative medicine sales infrastructure in countries where we currently do not commercialize the Celution System. Ultimately, our mutual goal is to broaden the relationship after we are able to better assess the market opportunities across several therapeutic indications and geographic regions.”
Partnership Terms
The partnership provides GE Healthcare with exclusive commercialization rights for 18 months in the U.K., France, Germany, Norway, Finland, Denmark, Sweden, Austria, and Switzerland for the cosmetic and reconstructive surgery market, translational medicine, and stem cell banking. The same terms apply in Belgium, The Netherlands and Luxembourg for translational medicine and stem cell banking. GE Healthcare was granted a two year right of first refusal to sales and distribution rights in the United States and all remaining European countries.
Adipose-Derived Stem & Regenerative Cells
Adipose, also known as fatty tissue is one of the most studied sources of adult stem cells. In addition to stem cells, there lies within adipose tissue a defined population of cell types that are also major contributors to healing, referred to as ‘regenerative cells.’ Together, these stem and regenerative cells represent tremendous opportunities for treating cardiovascular disease, spine and orthopedic disorders, and vascular conditions, reconstructive surgery and several other areas of medicine. Compared to other cell sources like umbilical cord blood and bone marrow, adipose tissue offers several advantages, including relative ease of accessibility, a high concentration of cells, and its amenability to real-time processing and autologous use without cell culture.
Cosmetic and Reconstructive Surgery
The Celution 800 was introduced in February 2008 into the European and Asia Pacific cosmetic and reconstructive surgery market. In this market, surgeons combine the Celution output with a patient’s own adipose tissue as a means to perform a cell-enhanced reconstruction or augmentation procedure. There is growing demand for the product among surgeons in Europe and Asia Pacific who are performing private-pay procedures. Additionally, several investigator-initiated studies and clinical cases are using the Celution System to perform small volume augmentations, breast implant salvage, and facial and dermal filler procedures.
There is a significant unmet medical need for viable reconstructive alternatives for women who undergo partial mastectomy as part of their breast cancer treatment. An estimated 375,000 patients in Europe are diagnosed each year with breast cancer, of which approximately 75% are eligible to undergo partial mastectomy. To pursue this market, Cytori is conducting a 70-patient, multi-center post-marketing study using the Celution System output for breast reconstruction in women who have undergone partial mastectomy.
Translational Medicine
The medical community is rapidly exploring the potential of adult stem cell-based therapies, as evidenced by the growing number of positive clinical outcomes being reported. The Celution System has the opportunity to serve as the technology of choice for accessing adult stem and regenerative cells, as it allows surgeons to work with their patient’s own cells, eliminating the risk of rejection or disease transmission. In addition, the device enables the cells to be processed and re-implanted in the same surgical procedure.
Meeting the demand for cells for translational medicine represents a meaningful market on its own. In addition, data from any investigator-initiated studies may benefit Cytori in the future by establishing and broadening the utility for the Celution System platform. In Japan, seven new investigator-initiated clinical studies using adipose-derived stem and regenerative cells have been approved by local ethical committees to be performed at academic university hospitals. These studies include vocal cord paralysis, chronic liver insufficiency, cirrhosis, radiation injury, and urinary incontinence.
StemSource® Cell Bank
A StemSource Cell Bank will allow hospitals, stem cell storage companies, or tissue banking labs to process and cryopreserve a patient’s own adipose-derived stem and regenerative cells when the cells are younger and more viable. StemSource cell banking services coupled with the real time Celution clinical cell therapy may ultimately allow hospitals to provide a broad array of regenerative medicine services to patients.
The foundation of the cell bank is Cytori’s Celution 900-MB System, which automates the processing of stem and regenerative cells from adipose tissue. This function facilitates the preparation and storage of the cells, thereby creating economic and process efficiencies that would otherwise make cell banking too expensive or time consuming for many patients.
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
cytx.png (verkleinert auf 79%)
Cytori Forms Commercialization Partnership with GE Healthcare
Last update: 7:00 a.m. EST Jan. 12, 2009
SAN DIEGO, Jan 12, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (CYTX:cytori therapeutics inc com
News , chart , profile , more
Last: 3.20+0.23+7.74%
12:42pm 01/21/2009
Delayed quote dataAdd to portfolio
Analyst
Create alert Insider
Discuss
Financials
Sponsored by:
CYTX 3.20, +0.23, +7.7%) today announced the formation of a partnership with GE Healthcare to commercialize Cytori's Celution(R) System in select European countries. The Celution System is a European-approved, state-of-the-art cell processing device, which extracts and makes a dose of a patient's own adipose tissue-derived adult stem and regenerative cells available at the point-of-care. As part of the new relationship, GE Healthcare will commercialize the Celution System in the areas of cosmetic and reconstructive surgery, translational medicine, and stem cell banking in combination with Cytori's StemSource(R) Cell Bank product.
"The addition of Cytori's Celution System to GE Healthcare's Cell Technologies portfolio demonstrates our commitment to the field," says Sarah Bork, Director for GE Healthcare's Cell Technologies Program. "Adipose tissue is emerging as one of the leading sources for adult stem and regenerative cells, and Cytori's Celution System can provide patients' own cells at the bedside. Its quality and ease-of-use, coupled with the demand from hospitals and surgeons for cells, underscore the growth potential of this system in regenerative medicine."
"GE Healthcare will immediately broaden our access to customers in Europe and should greatly expand our Celution System installed base," said Christopher J. Calhoun, chief executive officer for Cytori. "We will benefit from their existing hospital relationships and their established regenerative medicine sales infrastructure in countries where we currently do not commercialize the Celution System. Ultimately, our mutual goal is to broaden the relationship after we are able to better assess the market opportunities across several therapeutic indications and geographic regions."
The partnership provides GE Healthcare with exclusive commercialization rights for 18 months in the U.K., France, Germany, Norway, Finland, Denmark, Sweden, Austria, and Switzerland for the cosmetic and reconstructive surgery market, translational medicine, and stem cell banking. The same terms apply in Belgium, The Netherlands and Luxembourg for translational medicine and stem cell banking. GE Healthcare was granted a two year right of first refusal to sales and distribution rights in the United States and all remaining European countries.
Adipose-Derived Stem & Regenerative Cells
Adipose, also known as fatty tissue is one of the most studied sources of adult stem cells. In addition to stem cells, there lies within adipose tissue a defined population of cell types that are also major contributors to healing, referred to as 'regenerative cells.' Together, these stem and regenerative cells represent tremendous opportunities for treating cardiovascular disease, spine and orthopedic disorders, and vascular conditions, reconstructive surgery and several other areas of medicine. Compared to other cell sources like umbilical cord blood and bone marrow, adipose tissue offers several advantages, including relative ease of accessibility, a high concentration of cells, and its amenability to real-time processing and autologous use without cell culture
Die 3 sollten halten. Es ist bereits reichlich überverkauft.
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
cytx.png (verkleinert auf 79%)
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
cytx.png (verkleinert auf 79%)
Friday March 6, 6:05 pm ET
By Matthew Perrone, AP Business Writer
Stem cell developers surge on plans to reverse Bush research funding restrictions
WASHINGTON (AP) -- Shares of companies developing stem cell therapies surged Friday evening on word that President Obama on Monday is expected to overturn restrictions that have choked funding for academic stem cell research.
ADVERTISEMENT
President Obama pledged on the campaign trail to overturn the 2001 policy, which bans government funds for research that involves harvesting new embryonic stem cells. President George W. Bush, who set the policy, said the process is immoral because it destroys human embryos.
Industry executives have awaited an executive order from Obama to restore federal funding for the research. But some speculated the withdrawal of former Sen. Tom Daschle for the position of Secretary of Health and Human Services stalled the administration's plans.
A senior administration official said Friday the president will hold an event Monday at the White House to announce the move. The official spoke on condition of anonymity because the policy had not yet been publicly announced Friday.
"This is a very strong and powerful signal that we have a very user-friendly administration for stem cell research, and that will be hugely important going forward," said Richard Garr, president and CEO of Neuralstem Inc, a company working to develop a stem cell therapy for Lou Gehrig's disease.
Shares of Neuralstem and other biotech companies working with
Jetzt überverkauft in vielen Indikatoren verschiedener Zeitebenen. Nur was nützt das, wenn die Finanzierungslage weiterhin angespannt ist und auch der Groß-Aktionär Olympus aktuell mit massiven Verlusten zu kämpfen hat?
Ab nächstes Jahr soll das Neue cellutionmodell verkauft werden, bisher ist es ja eher "gebastel". Vielleicht hemmt aber genau das die Verkäufe 2009?
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
cytx.png (verkleinert auf 79%)
Zeitpunkt: 14.07.12 11:17
Aktion: Löschung des Beitrages
Kommentar: Erotischer Inhalt
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
Wurde früher abgesaugtes Eigenfett achtlos weggeworfen, können dank
modernster medizinischer Technologie die im Fett vorhandenen körpereigenen Stammzellen zur Verjüngung und Körperformung genutzt werden. "Aus Eigenfett gewonnene körpereigene Stammzellen eignen sich zur natürlichen Brustvergrößerung und besitzen überdies ein unermeßliches regeneratives Potential", sagt DDr. Karl-Georg Heinrich, Experte für kosmetische Chirurgie und Anti-Aging aus Wien.
Zunächst wird Körperfett schonend mit speziellen patentierten Mikrokanülen entnommen. Aus einem Teil des abgesaugten Eigenfettes werden Stammzellen extrahiert und mit dem Rest des Fettes vermengt. Anschließend wird das Stammzell-angereicherte Eigenfett mit dünnen Injektionsnadeln in die Brust injiziert: Ganz ohne Skalpell, unansehnliche Narben und implantierte Fremdkörper. Aus den Stammzellen entsteht neues, lebendes Gewebe.
Die mit Stammzell-angereichertem Eigenfett vergrößerte Brust fühlt sich - da die Volumszunahme nicht aus Silikon, sondern aus körpereigenem Fettgewebe besteht - völlig natürlich an und sieht auch in jeder Position "echt" aus. Sowohl die Fettabsaugung mit gewebeschonenden Mikrokanülen als auch die Brustvergrößerung können innerhalb weniger Stunden unter Lokalanästhesie oder im Dämmerschlaf vorgenommen werden. Der Nachsorgeaufwand ist minimal; die Patientin wird nach dem Eingriff nach Hause entlassen. Sicherheit des Eingriffs und Dauerhaftigkeit des Ergebnisses belegen klinische Studien aus den USA und Japan.
In der Ordination Clinic DDr. Heinrich wird Stammzell-angereichertes Eigenfett außerdem zum natürlichen Body-Forming an anderen Körperregionen wie Po, Hüften, Oberschenkel, Waden etc. sowie zur Dellenkorrektur und Hautverjüngung an Gesicht, Dekolleté und Händen eingesetzt.
Weitere Informationen unter http://www.liposkulptur.at
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
Optionen
| Boardmail an "Vermeer" |
Wertpapier: Cytori Therapeutics |
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
Man muss ja nicht überall mitmachen.
Optionen
| Boardmail an "Vermeer" |
Wertpapier: Cytori Therapeutics |
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |